// App-Quantinova.ai

8524 : Programmed cell death-1 ligand (PD-L1) expression on circulating CD45(-) cells is an independent prognostic factor for overall survival in patients (Pts) with lung cancer in a prospective, multicenter cohort.

Researchers

Presenter

  • Daniel J Boffa

Principal Investigators

  • Jorge J. Nieva

  • Lyudmila Bazhenova

  • Rachel Krupa

  • David Lu

  • Ryon Graf

  • Jessica Louw

  • Lyndsey Dugan

  • Adam Jendrisak

  • Michelle Salazar

  • Samir Makani

  • Marisa Magana

  • Sarah Orr

  • Kelly Bethel

  • Yipeng Wang

  • Dena C. Marrinucci

  • Ryan Vance Dittamore

Medical Centers

  • Yale University School of Medicine, New Haven, CT

  • University of Southern California, Los Angeles, CA

  • Center for Personalized Cancer Therapy and Division of Hematology and Oncology, UCSD Moores Cancer Center, La Jolla, San Diego, CA

  • Epic Sciences, Inc., San Diego, CA

  • Yale University School of Medicine, New Haven, CT

  • UCSD School of Medicine, San Diego, CA

  • Scripps Clinic Medical Group/Scripps Health, La Jolla, CA

  • Epic Sciences, Inc., San Diego, CA

Locations

  • United States

Companies

  • EPIC SCIENCES, INC.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Lung Cancer

Biomarkers

  • Cluster of differentiation 45

  • Programmed death-ligand 1

Drug/Treatment

  • N/A

Outcome

  • Unknown

Study Design

  • Multicenteric

  • Prospective

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved